Zenas BioPharma, Inc. 8-K

What Happened

• Zenas BioPharma announced it closed a $200.0 million offering of 2.50% Convertible Senior Notes due April 1, 2032 (the "Notes") and a concurrent equity offering of 5,000,000 shares of common stock (5/31/26 closings dated March 31, 2026). The Notes were issued under an indenture with U.S. Bank Trust Company, N.A. as trustee. Net proceeds were approximately $193.7 million from the Notes and approximately $93.7 million from the equity sale (5M shares at $20.00 per share before underwriting discounts). The company granted underwriters options to purchase up to an additional $30.0M of Notes and up to 750,000 additional shares for over-allotments.

Key Details

• Convertible Note terms: 2.50% annual interest, payable semiannually on April 1 and October 1 beginning Oct 1, 2026; maturity April 1, 2032.
• Initial conversion rate: 37.7358 shares per $1,000 principal (≈ $26.50 per share conversion price); maximum initial shares that may be issued upon conversion is 11,500,000 based on a higher initial maximum conversion rate (50.0000 shares/$1,000) subject to adjustments.
• Conversion and redemption triggers: noteholders can convert only in specified circumstances (e.g., certain stock‑price tests, corporate events, during limited post‑call or pre‑maturity windows); company may redeem notes beginning April 8, 2030 under specified conditions (including stock-price tests).
• Special interest remedy for certain reporting failures: if the company fails to meet certain reporting covenants, noteholders’ sole remedy may be special interest for up to 365 days — 0.25% per annum for the first 180 days, then 0.50% per annum thereafter.
• Use of proceeds: company stated proceeds will support a planned U.S. commercial launch of obexelimab (if approved), advance orelabrutinib Phase 3 trials and ZB021 development, plus working capital and general corporate purposes.

Why It Matters

• The financings provide Zenas with substantial near‑term capital (net ~ $287.4M combined) to fund clinical programs, potential commercialization plans, and general operations — important given the company's prior disclosures about needing additional financing.
• Investors should watch potential dilution and timing: the Notes can convert into common stock under defined triggers (so conversion would increase outstanding shares), and the company also completed an equity sale. Redemption, repurchase on certain corporate transactions, and conversion adjustments could affect future share count and cash flow.
• Key risks and protections are included in the indenture (Events of Default, repurchase rights on Fundamental Changes, and special‑interest remedies for reporting lapses). The legal opinions for both offerings (Ropes & Gray) are filed as exhibits to the 8‑K.